Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Department of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medical, Jinan, Shandong, China.
Front Immunol. 2024 Apr 8;15:1340908. doi: 10.3389/fimmu.2024.1340908. eCollection 2024.
Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).
Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 10/L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group.
A total of 51 patients who applied TPO during the same period were treated as a control. In the eltrombopag group, the median time to white blood cells (WBC) graft was 12 days (range, 10-17 days) and the PLT graft was 15 days (range, 10-30 days), whereas for the patients in the TPO group, the median time to WBC and PLT graft was 12 days (range, 9-23 days) and 15.5 days (range, 9-41 days), respectively. In the first month after HSCT, the median WBC count in the eltrombopag group was 4.41 × 10/L (range, 0.87-40.01 × 10/L) and the median PLT was 89x10/L (range, 30-401 × 10/L); the median WBC and PLT \counts in the TPO group were 4.65 × 10/L (range, 0.99-23.63 × 10/L) and 86 × 10/L (range, 5-512 × 10/L), respectively. Patients in the TPO or eltrombopag group did not experience serious side effects after drug administration, and the difference in side effects on liver and kidney function between the two groups was not statistically significant.
Eltrombopag is safe and similarly promotes platelet engraftment to thrombopoietin after allogeneic HSCT.
依洛尤单抗已被证明可有效治疗血小板（PLT）水平降低，但对于依洛尤单抗是否可促进造血干细胞移植（HSCT）后 PLT 植入仍不清楚。
41 例 HSCT 患者从+1 天开始接受 50mg/d 的依洛尤单抗治疗，直至 PLT>50×10/L 或 HSCT 后 1 个月。同期 51 例患者接受促血小板生成素（TPO）以促进 PLT 移植物，并作为对照组。
同期接受 TPO 治疗的 51 例患者作为对照组。依洛尤单抗组白细胞（WBC）植入的中位时间为 12 天（范围 10-17 天），血小板植入的中位时间为 15 天（范围 10-30 天），而 TPO 组 WBC 和 PLT 植入的中位时间分别为 12 天（范围 9-23 天）和 15.5 天（范围 9-41 天）。HSCT 后第一个月，依洛尤单抗组的中位 WBC 计数为 4.41×10/L（范围 0.87-40.01×10/L），中位 PLT 计数为 89×10/L（范围 30-401×10/L）；TPO 组的中位 WBC 和 PLT 计数分别为 4.65×10/L（范围 0.99-23.63×10/L）和 86×10/L（范围 5-512×10/L）。两组患者用药后均未发生严重不良反应，且两组肝肾功能不良反应差异无统计学意义。
依洛尤单抗是安全的，与 TPO 一样，可促进异基因 HSCT 后血小板植入。
